Suven Pharmaceuticals Renamed as Cohance Lifesciences
ECONOMY & POLICY

Suven Pharmaceuticals Renamed as Cohance Lifesciences

Suven Pharmaceuticals, an integrated CDMO serving customers across the globe, has rebranded as Cohance Lifesciences.

This event represents more than just a name change—it marks a bold step forward in the company’s evolution into a specialized, technology-driven global CDMO platform, purpose-built for the future of therapeutics.

The Cohance name captures the organization’s commitment to Collaborate with global innovators to Enhance their molecules and products to deliver transformative solutions to patients and consumers worldwide.

"The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world" said Cohance Executive Chairman, Vivek Sharma.

The Ministry of Corporate Affairs, Government of India (“MCA”), has approved change of name of the Company from “Suven Pharmaceuticals” to “Cohance Lifesciences”, with effect from May 7, 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation.

The Company would make necessary application to the BSE and the National Stock Exchange of India Limited for effecting change of name of the Company in due course. We further inform that the Name Clause of the Memorandum of Association of the Company stands altered accordingly, and the name “Suven Pharmaceuticals” wherever it appears in the Memorandum of Association and the Articles of Association, gets replaced with the new name “Cohance Lifesciences.”

Suven Pharmaceuticals, an integrated CDMO serving customers across the globe, has rebranded as Cohance Lifesciences. This event represents more than just a name change—it marks a bold step forward in the company’s evolution into a specialized, technology-driven global CDMO platform, purpose-built for the future of therapeutics. The Cohance name captures the organization’s commitment to Collaborate with global innovators to Enhance their molecules and products to deliver transformative solutions to patients and consumers worldwide. The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world said Cohance Executive Chairman, Vivek Sharma. The Ministry of Corporate Affairs, Government of India (“MCA”), has approved change of name of the Company from “Suven Pharmaceuticals” to “Cohance Lifesciences”, with effect from May 7, 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation. The Company would make necessary application to the BSE and the National Stock Exchange of India Limited for effecting change of name of the Company in due course. We further inform that the Name Clause of the Memorandum of Association of the Company stands altered accordingly, and the name “Suven Pharmaceuticals” wherever it appears in the Memorandum of Association and the Articles of Association, gets replaced with the new name “Cohance Lifesciences.”

Next Story
Infrastructure Transport

India Becomes First to Produce Bio-Bitumen for Roads

India has become the first country in the world to commercially produce bio-bitumen for use in road construction, according to Road, Transport and Highways Minister Nitin Gadkari. Bitumen, a black and viscous hydrocarbon derived from crude oil, is a key binding material in road building, and the bio-based alternative is expected to significantly improve the sector’s environmental footprint.Addressing the CSIR Technology Transfer Ceremony in New Delhi, Mr Gadkari congratulated Council of Scientific and Industrial Research on achieving the milestone, noting that the initiative would help curb ..

Next Story
Infrastructure Urban

HILT Policy Seen Boosting Telangana Revenue Sharply

The Hyderabad Industrial Land Transformation (HILT) Policy is expected to generate around Rs 1.08 billion in revenue for the Telangana state exchequer, according to Deputy Chief Minister Bhatti Vikramarka Mallu. Speaking in the Telangana Legislative Assembly, he said the policy would be implemented within a six-month timeframe in a transparent manner, with uniform rules applicable to all stakeholders. Mr Vikramarka noted that without the HILT Policy, the state would have earned only about Rs 1.2 million per acre. Under the new framework, however, revenue is projected to rise sharply to Rs 70 ..

Next Story
Infrastructure Urban

India Post, MoRD Tie Up to Boost Rural Inclusion

The Department of Posts and the Ministry of Rural Development have signed a Memorandum of Understanding to accelerate rural transformation and expand financial, digital and logistics services for Self-Help Groups (SHGs) and rural households across India. The agreement was signed in the presence of Union Minister of Communications and Development of North Eastern Region Jyotiraditya M. Scindia and Union Minister of Rural Development and Agriculture and Farmers’ Welfare Shivraj Singh Chouhan. The collaboration aligns with the government’s “Dak Sewa, Jan Sewa” vision and seeks to repositi..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Open In App